

Attendee List Released for Superbugs 2017 Featuring FDA, GSK, MHRA, Merck and Abbott

Industry set to gather in just four weeks for 19th annual industry summit on antimicrobial resistance

LONDON, ENGLAND, UNITED KINGDOM, February 22, 2017 /EINPresswire.com/ -- With just 4 weeks to go, an attendee list featuring an international audience of AMR experts and scientific pioneers has been released ahead of SMi's long running 19th annual summit on <u>Superbugs &</u> <u>Superdrugs</u>.

The industry calendar highlight on antibiotic resistance will provide a platform for attendee's to network, exchange novel solutions and consolidate current strategy.

Notable sessions on the agenda include:

1. Guidance on common governing pitfalls presented by the FDA.

"

2. Strategies to enable drug discovery



through identifying a novel class of broad spectrum antibacterials and statistical approaches in drug development.

3. 12+ hours of content on new innovations such as antimicrobial peptides and DNA topoisomerases.4. A keynote to facilitate research from bench to bedside with a detailed spotlight on the latest

government incentives and funding opportunities presented by the US governing body - BARDA.

 Cutting edge progress through insight into both compound and non compound approaches from European case studies.
Insight into eradicating specific bacterial pathogens while sparing the beneficial microbiota in a keynote on sequence specific antimicrobials.

Some of those confirmed to attend include:

Martin Everett, Chief

Scientific Officer, Antabio

I find all the sessions relevant

and interesting"

Abbott Medical optics Uppsala AB | Aberdeen University and Grampian University Hospitals | Achaogen Inc | AiCuris Anti-infective Cures GmbH | Alacrita LLP | Allecra Therapeutics SAS | Antabio | Arsanis Biosciences GmbH | Auspherix Ltd | BARDA | Chemical Biology Ventures | Colzyx | Da Volterra | Danestat consulting | DeNovaMed Inc | Discuva | Drugs for Neglected Diseases initiative (DNDi) | DSTL Porton Down | Eligo Bioscience | FDA | GSK | John Innes Centre | JSC R-PHARM | King khaled eye specialist hospital | King's College London | KWS BioTest | Merck | MHRA | Micromyx LLC | Motif Bio | Mrc Technology | Neem Biotech | Novabiotics Ltd | Novo AS | PHARMA OMNIUM | Phico Therapeutics Ltd | Procarta Biosystems Ltd. | SA Pathology | Spero Therapeutics | St George's, University of London | Synthetic Biologics, Inc. | Tiber Creek Partners, LLC | TranScrip Partners | University College Cork | University of Cambridge | University of North Texas Health Science Center | X-Biotix Therapeutics | Zambon Spa

A preliminary list of attendee's is available to download in the event download centre.

Further information is available at: <u>www.superbugssuperdrugs.com</u>

Superbugs & Superdrugs 20th & 21st March 2017 Copthorne Tara Hotel, London, UK Sponsored by MSD and Synthetic Biologics, Inc

--- end ---

Contact Information:

For all media inquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk For delegate inquiries contact Fateja Begum on Tel: +44 (0)20 7827 6184 / Email: fbegum@smionline.co.uk

For exhibition and sponsorship inquiries contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Teri Arri SMi Group 2078276000 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2017 IPD Group, Inc. All Right Reserved.